Related Experiment Video
Updated: Aug 13, 2026
Flow Cytometry-based Assay for the Monitoring of NK Cell Functions
Published on: October 30, 2016
Effect of isotretinoin therapy on natural killer cell activity in patients with xeroderma pigmentosum
J H Anolik1, J J Di Giovanna, A A Gaspari
1Department of Dermatology, National Institute of Arthritis, Musculoskeletal and Skin Diseases, National Institutes of Health, USA.
Abstract:
Xeroderma pigmentosum (XP) is a rare autosomal recessive disorder characterized by sun sensitivity, defective DNA repair, markedly increased susceptibility to skin cancer, and a variety of immunological defects, including defective natural killer (NK) cell activity. Retinoid therapy has been demonstrated to protect effectively against the development of skin cancers in patients with XP, although its mechanism of action is unknown. We describe a series of eight XP patients, six of whom were given oral isotretinoin. The NK cell activity was not affected by low-dose isotretinoin, i.e. 0.5 mg/kg per day. However, higher doses of isotretinoin, e.g. 1.0 mg/kg per day, produced a significant decrease in NK cell function, at the same time as producing a reduction in the frequency of development of skin cancers. Retinoid therapy may have a skin cancer preventing effect by enhancing other immune effector mechanisms or via epithelial cell differentiation.
Insights
Higher doses of isotretinoin reduced skin cancer development in Xeroderma pigmentosum (XP) patients, despite decreasing natural killer (NK) cell activity. This suggests retinoid therapy may protect against XP skin cancers through alternative immune pathways.
Area of Science:
- Genetics and Immunology
- Dermatology and Oncology
Background:
- Xeroderma pigmentosum (XP) is a rare genetic disorder causing extreme sun sensitivity and increased skin cancer risk.
- XP patients exhibit defective DNA repair and impaired immune function, including reduced natural killer (NK) cell activity.
- Retinoid therapy shows promise in preventing skin cancers in XP patients, but its mechanism remains unclear.
Purpose of the Study:
- To investigate the effect of isotretinoin dosage on NK cell activity and skin cancer incidence in XP patients.
- To explore potential mechanisms of retinoid therapy in mitigating skin cancer development in XP.
Main Methods:
- Observational study of eight XP patients, with six receiving oral isotretinoin.
- Dosage levels of isotretinoin administered were 0.5 mg/kg/day (low-dose) and 1.0 mg/kg/day (higher-dose).
- Assessment of NK cell activity and monitoring of skin cancer development frequency.
Main Results:
- Low-dose isotretinoin (0.5 mg/kg/day) did not significantly alter NK cell activity.
- Higher-dose isotretinoin (1.0 mg/kg/day) led to a significant decrease in NK cell function.
- Concurrently, higher-dose isotretinoin treatment correlated with a reduced frequency of skin cancer development in XP patients.
Conclusions:
- Higher-dose isotretinoin therapy may reduce skin cancer incidence in XP patients.
- The cancer-preventing effect of retinoids in XP might involve mechanisms beyond direct enhancement of NK cell activity.
- Further research is needed to elucidate the precise immune-modulating effects of retinoids in XP.
Related Concept Videos
01:27Cytotoxic T Cells-mediated Immune Response
Immunological surveillance is the ability of immune cells to monitor and eliminate infected cells with intracellular pathogens, neoplastically transformed cells, and cells with non-self antigens. Cytotoxic T cells and NK...
01:27Acne Infection